This orally bioavailable selective inhibitor of Bcl‐2 was shown to cause cell death in chronic lymphocytic leukaemia (CLL) cells with an EC50 < 10 nM (Souers et al.,2013). The gene discussed is BCL2; the disease is B-cell chronic lymphocytic leukemia.